MedInCell Stock Rises 4% and Crosses a Key Technical Threshold at Midday
On Tuesday, the stock of the Montpellier-based biotech company showed a significant increase to 24.32 euros, in a generally bullish market environment. This rebound occurs as the CAC 40 gains 0.60% during the session and the stock had lost nearly 8% over the last three months.
At midday, MedInCell's stock trades at 24.32 euros, up 4.02% from the previous close of 23.38 euros. The stock has just crossed the upper Bollinger Band threshold at 23.91 euros, a level indicating potential overbuying when the price moves above this threshold. Simultaneously, the price exceeds its 200-day moving average (23.67 euros) and positions itself well beyond the MM50 (22.77 euros), reflecting a short-term bullish reversal after several weeks of decline. The previous resistance at 23.62 euros has also been cleared, now setting this level as a new potential support to watch. The RSI, at 57, remains in a neutral zone and does not yet indicate extreme tension on the stock, despite exceeding the upper Bollinger Band. Over a week, the gain reaches 5.28%, bringing the annual performance to nearly 89.4%. The monthly volatility is set at 14.53%, a relatively moderate level for a biotech sector stock.
Key Upcoming Dates for MedInCell Stockholders
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The next key date for MedInCell stockholders is set for June 16, 2026, the date of the annual results publication for the fiscal year 2025-2026. This schedule marks an important milestone to assess the commercial trajectory of the company specialized in long-term injection technologies. The general assembly is scheduled for September 10, 2026, followed by the results of the first half of 2026-2027 planned for December 8. In the European pharmaceutical sector, performances vary this Tuesday: Sanofi is up by 0.48% while UCB is down by 0.18%. MedInCell's negative beta (-0.14) highlights its low correlation with major indices, making it a stock whose movements are largely dictated by its own catalysts rather than the general market trend. On the American side, investors in the pharma sector can also keep an eye on Eli Lilly, Johnson & Johnson, and AbbVie.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
